Use access key #2 to skip to page content.
$3.40 0.02 (0.59%)
9/5/2008 4:00 PM

SIGA Technologies, Inc. (SIGA)

CAPS Rating:
*

A bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents such as Smallpox and Arenaviruses.

View All Commentary (SIGA)

Recs

1

Avatar tomcatbubba (< 20) Submitted: 5/31/07 9:22 PM : Outperform Start Price: $3.81 SIGA Score: 8.38

This is why I have love this stock and have been following it for a year now.


1) SIGA-246, its smallpox vaccine, is the industry leading vaccine that is NOT made from a live virus (hence you cannot contract the virus).


2) SIGA-246 just passed its safety trials and its orphan drug status with the FDA, so the government can start stockpiling under Project Bioshield.


3) Project Bioshield allows for $1.65 Billion for U.S. stockpiles of the smallpox vaccine by 2013.


4) SIGA-246 was actually given to a two year old boy who contacted a derivative of smallpox from his father who is in the Army and was recently vaccinated. The CDC thought so highly of SIGA-246 they allowed the boy to receive the drug. After two days he was out of intensive care. PR disaster for the Pentagon, but HUGE for SIGA.


I expect SIGA to reach $12-18 in the next 12 months after government contracts begin to roll in. Expect a buyout by a large Pharm. in the next 2-5 years.

Report this Post Replies: 0 | Reply

Featured Broker Partners